Amundi
NGM

Amundi’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Amundi’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,407
Closed -$93K – 2001
2022
Q3 		$93K Hold
7,407
– – ﹤0.01% 1572
2022
Q2 		$115K Buy
+7,407
New +$103K ﹤0.01% 1426

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amundi's NGM Position: Q4 2022 in Review

Amundi sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 7,407 shares — an estimated $93K sold.

Amundi first reported a position in NGM in Q2 2022 and held it in 2 quarters. The position peaked at $115K in Q2 2022. 125 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

  • Amundi reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Amundi sold 7,407 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $93K.
  • Amundi first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Amundi's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $115K in Q2 2022.
  • 125 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Amundi's 13F filing for Q4 2022, filed 14 Feb 2023.